Common TitleTARGET
Official Title Combivir, Abacavir (1592U89), Amprenavir (141W94) Triple Antiretroviral, Experienced Patient Trial
Phase Phase IV
ClinicalTrials.gov NCT00002217
Treatments
Abacavir-Lamivudine-Zidovudine
Abacavir-Lamivudine-Zidovudine
Tradename:TrizivirOther Names:ABC-3TC-ZDVClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories Treatment-Experienced
Funding
IndustryGlaxo Wellcome
References
- Henry K, Wallace RJ, Bellman PC, et al. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. J Infect Dis. 2001;183:571-8.